Clin2
NCT07261592Possibly a fitNot yet recruiting

Entinostat plus chemo for advanced bladder cancer

Bladder CancerHistone Deacetylase InhibitorEntinostatChemotherapy

Treatments studied

Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.

This study tests a new drug called entinostat combined with standard chemotherapy for bladder cancer that has spread and no longer responds to the first treatment. It may help shrink tumors or slow the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
29 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Your bladder cancer must be the common type (not squamous or glandular).
  • You’ve tried one first treatment for advanced cancer, and it didn’t work (but you haven’t had platinum chemotherapy afterward).
  • You have at least one tumor that can be measured on a scan.
  • You have stored tumor tissue from a past biopsy, or can get a new one.
  • You are active enough to do daily tasks (ECOG score 0 or 1) and expected to live at least 6 more months.
  • If you could become pregnant, you agree to use birth control during the study and for 6 months after.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06091124Recruiting· Phase 2
Immunotherapy plus chemo before surgery for neuroendocrine bladder cancer

This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.

Nanjing, Jiangsu
NCT06364904Not yet recruiting· Phase 3
Immunotherapy plus chemo for advanced bladder cancer

This trial tests a new combination of immunotherapy (tislelizumab) plus chemotherapy (cisplatin and gemcitabine) with or without an extra drug (trilaciclib) for people with advanced bladder cancer that hasn't been treated yet. The goal is to see if this combination is safe and helps shrink tumors.

Guangzhou, Guangdong
NCT07232602Recruiting· Phase 1/Phase 2
New drug combinations for advanced bladder cancer

This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.

San Francisco, California
NCT05312671Recruiting· Phase 2
Atezolizumab plus chemo for small cell bladder cancer

This trial studies whether a drug called atezolizumab combined with chemotherapy (etoposide and a platinum drug) can shrink or control small cell bladder cancer. It may help by boosting the immune system against the cancer while the chemotherapy treats fast-growing cancer cells.

Washington D.C., District of Columbia
NCT07419295Recruiting· Phase 3
Testing a new drug for advanced bladder cancer

This trial is for people with advanced bladder cancer (urothelial cancer) that has spread or can't be removed. It tests a new drug called sacituzumab tirumotecan against standard chemotherapy options to see if it works better.

Traverse City, Michigan
NCT06394570Recruiting· Phase 1/Phase 2
Enfortumab vedotin and radiation for bladder cancer

This trial tests a combination of a targeted drug (enfortumab vedotin) and focused radiation before surgery to remove the bladder. It is for people with muscle-invasive bladder cancer who cannot take cisplatin chemotherapy.

Dallas, Texas

Hear when a new Bladder Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.